Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under which Pfizer...

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...

Stephen Hansen, Associate Editor Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...

Pfizer purchased a 17.5% equity stake in AM-Pharma and received an option acquire the remainder of the company. The option is exercisable upon completion of a Phase II trial of AM-Pharma’s recAP recombinant alkaline phosphatase...

Pfizer Inc. (NYSE:PFE) purchased an equity stake in renal company AM-Pharma B.V. (Bunnik, the Netherlands) and obtained an exclusive option to acquire the remainder of the company. Pfizer can exercise the option when an ongoing...

AM-Pharma began the double-blind, placebo-controlled, international Phase II STOP-AKI trial to evaluate 0.4, 0.8 and 1.6 mg/kg IV RecAP once daily for 3 days in about 290 patients with sepsis-associated AKI. A dose-finding part will...